Can-Fite BioPharma (NYSE:CANF) Downgraded to “Sell” at StockNews.com

StockNews.com lowered shares of Can-Fite BioPharma (NYSE:CANF) from a hold rating to a sell rating in a report issued on Monday.

Separately, EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a strong-buy rating in a research report on Wednesday, July 17th.

Can-Fite BioPharma Trading Up 2.4 %

CANF stock opened at $2.52 on Monday. The firm’s 50-day moving average price is $2.27 and its two-hundred day moving average price is $2.48. The stock has a market capitalization of $8.92 million, a price-to-earnings ratio of -1.41 and a beta of 1.41. Can-Fite BioPharma has a 12-month low of $1.81 and a 12-month high of $4.69.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.